A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare two different anti-HIV drug combinations, one that contains nelfinavir (NFV) and one that does not. The best dosing schedule for indinavir (IDV) also will be studied.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Indinavir; Lamivudine; Nelfinavir; Stavudine

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are HIV positive.

• Have a viral load (level of HIV in your blood) of at least 10,000 copies/ml within 45 days of study entry.

• Have a CD4 cell count of at least 100 cells/mm3 within 45 days of study entry.

• Have a normal chest X-ray.

• Have never taken protease inhibitors or 3TC.

• Are 16 years of age or older.

• Agree to practice sexual abstinence or use barrier methods of birth control (e.g., condoms).

Exclusion Criteria

You will not be eligible for this study if you:

• Have an active opportunistic (AIDS-related) infection or cancer.

• Have certain types of Kaposi's sarcoma.

• Have hepatitis.

• Have chronic diarrhea.

• Have a history of certain medical conditions.

• Are allergic to any of the study medications.

• Are taking certain medications.

• Are pregnant or breast-feeding.